This site is intended for US healthcare professionals only.

Learn more about ZYFLO connect and save on your co-pay

ZYFLO CR® (zileuton) has proven efficacy

ZYFLO CR® significantly improved lung function¹

Adapted from Nelson H, et al. Ann Allergy Asthma Immunol. 2007.
  • ZYFLO CR® achieved a 21% improvement in FEV1 at 12 weeks (P=0.03)
  • ZYFLO CR® achieved a 13% improvement in FEV1 at the first study time point of 2 weeks (P<0.01)
  • ZYFLO CR® achieved a 44% increase in FEV1 volume at 12 weeks (P=0.02)
  • ZYFLO CR® significantly reduced use of SABA rescue therapy (n=199; P=0.009)¹
  • ZYFLO CR® is contraindicated in patients with active liver disease or transaminase elevations ≥3 times the upper limit of normal.

Please see Important Safety Information and Full Prescribing Information.

*See ZYFLO connect® Terms and Conditions

Reference: 1. Nelson H, Kemp J, Berger W, et al. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. Ann Allergy Asthma Immunol. 2007;99:178-184.